Literature DB >> 27130438

Protein degradation in a LAMP-2-deficient B-lymphoblastoid cell line from a patient with Danon disease.

Raul Sánchez-Lanzas1, Beatriz Alvarez-Castelao1, Teresa Bermejo1, Teresa Ayuso2, Teresa Tuñón3, José G Castaño4.   

Abstract

Danon disease, a condition characterized by cardiomyopathy, myopathy, and intellectual disability, is caused by mutations in the LAMP-2 gene. Lamp-2A protein, generated by alternative splicing from the Lamp-2 pre-mRNA, is reported to be the lysosomal membrane receptor essential for the chaperone-mediated autophagic pathway (CMA) aimed to selective protein targeting and translocation into the lysosomal lumen for degradation. To study the relevance of Lamp-2 in protein degradation, a lymphoblastoid cell line was obtained by EBV transformation of B-cells from a Danon patient. The derived cell line showed no significant expression of Lamp-2 protein. The steady-state mRNA and protein levels of alpha-synuclein, IΚBα, Rcan1, and glyceraldehyde-3-phosphate dehydrogenase, four proteins reported to be selective substrates of the CMA pathway, were similar in control and Lamp-2-deficient cells. Inhibition of protein synthesis showed that the half-life of alpha-synuclein, IΚBα, and Rcan1 was similar in control and Lamp-2-deficient cells, and its degradation prevented by proteasome inhibitors. Both in control and Lamp-2-deficient cells, induction of CMA and macroautophagy by serum and aminoacid starvation of cells for 8h produced a similar decrease in IΚBα and Rcan1 protein levels and was prevented by the addition of lysosome and autophagy inhibitors. In conclusion, the results presented here showed that Lamp-2 deficiency in human lymphoblastoid cells did not modify the steady-state levels or the degradation of several protein substrates reported as selective substrates of the CMA pathway.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alpha-synuclein; Autophagy; Chaperone-mediated autophagy; Danon disease; IkappaB; LAMP-2; Rcan1; Ubiquitin proteasome; glyceraldehyde-3-phosphate dehydrogenase

Mesh:

Substances:

Year:  2016        PMID: 27130438     DOI: 10.1016/j.bbadis.2016.04.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

1.  Ganglioside Metabolism and Parkinson's Disease.

Authors:  John Forsayeth; Piotr Hadaczek
Journal:  Front Neurosci       Date:  2018-02-05       Impact factor: 4.677

2.  Inhibitors of lysosomal function or serum starvation in control or LAMP2 deficient cells do not modify the cellular levels of Parkinson disease-associated DJ-1/PARK 7 protein.

Authors:  Raúl Sánchez-Lanzas; José G Castaño
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.